Perspectives in camptothecin development

Bibliography

• BAILLY C: Topoisomerase I poisons and suppressors as anticancer drugs. Corr. Med. Chem. (2000) 7:39–58
   PubMed Web of Science ®Google Scholar
• POMMIER Y, POURQUIER E FAN Y, STRUMBERG D: Mechanism of action of eukariotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta (1998) 1400:83–106.
   PubMed Web of Science ®Google Scholar
• LIU LF, DESAI SD, LI TK, MAO Y, SUN M, SIM SP: Mechanism of action of camptothecin in The Camptothecins. Unfolding their Anti-Cancer potential. Liehr JG, Giovanella BC, Verschraegen CF (Eds), New York Academy of Sciences, USA (2000) 922:1–10.
   PubMed Web of Science ®Google Scholar
• CAPRANICO G, ZUNINO F: Antitumor inhibitors of DNA topoisomerases. Curl: Pharm. Design (1995) 1:1–14.
   Google Scholar
• ROTHENBERG ML: Topoisomerase I inhibitors: review and update. Ann. Oncol. (1997) 8:837–855.
   PubMed Web of Science ®Google Scholar
• DARZYNKIEWICZ Z, BRUNO S, DEL BINO G, TRAGANOS F: The cell cycle effects of camptothecin. In: The Camptothecins. From discovery to the patient. Pantazis E Giovanella BC, Rothenberg ML (Eds), New York Academy of Sciences (1996) 803:93–110.
   Google Scholar
• LIU LF, DUANN P, LIN C, DARPA P,WU J: Mechanism of action of camptothecin. In: The Camptothecins. From discovery to the patient. Pantazis P, Giovanella BC, Rothenberg ML (Eds), New York Academy of Sciences, USA (1996) 803:44–49.
   Google Scholar
• GIOVANELLA BC, NATELSON E, HARRIS N, VARDEMAN D, STEHLING JS: Protocols for the treatment of human tumor xenografts with camptothecins. In: The Camptothecins. From discovery to the patient. Pantazis P, Giovanella BC, Rothenberg ML (Eds), New York Academy of Sciences, USA (1996) 803:181–187.
   Google Scholar
• MUGGIA FM, DIMERY I, ARBUCK SG:Camptothecin and its analogs: an overview of their potential in cancer therapeutics. In: The Camptothecins. From discovery to the patient. Pantazis P, Giovanella BC, Rothenberg ML (Eds), New York Academy of Sciences, USA (1996) 803:213–223.
   Google Scholar
• DALLAVALLE S, DELSOLDATO T, FERRARI A etal.: Novel 7-substituted camptothecins with potent antitumor activity. ..1 Med. Chem. (2000) 43:3963–3969.
   Google Scholar
• DALLAVALLE S, FERRARI A, BIASOTTI B et al.: Novel 7-Oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. ..1 Med. Chem. (2001) 44:3264–3274.
   Google Scholar
• •This paper shows that lipophilic chains in position 7 of CPT give high cytotoxicity related to increased persistence of the DNA-Topo I cleavable complex.
   Google Scholar
• DE CESARE M, PRATESI G, PEREGO P et al.: Potent antitumor activity and improved pharmacological profile of 5T1481, a novel 7-substituted camptothecin. Cancer Res. (2001) 61:7189–7195.
   PubMed Web of Science ®Google Scholar
• BOM D, CURRAN DE KRUSZEWSKI S et al.: The novel silatecan 7-tert-butyldimethylsily1-10-hydroxycamptothecin displays high liphophilicity, improved human blood stability, and potent anticancer activity. ..1 Med. Chem. (2000) 43:3970–3980.
   Google Scholar
• •This paper reports the total synthesis of very active lipophilic 10-hydroxy-7-silp CPT derivatives, with increased drug stability in the presence of HSA.
   Google Scholar
• POLLACK IF, ERFF M, BOM D, BURKE TG, STRODE JT, CURRAN DP: Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res. (1999) 59:4898–4905.
   PubMed Web of Science ®Google Scholar
• VAN HATTUM AH, PINEDO HM, SCHLUPER HMM, HAUSHEER FH, BOVEN E: New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int...1 Cancer (2000) 88:260–266.
   PubMed Web of Science ®Google Scholar
• LAVERGNE O, LESUEUR-GINOT L, PLA RODAS F et al.: Homocamptothecins: synthesis and antitumor activity of novel E- ring modified camptothecin analogues.j Med. Chem. (1998) 41:5410–5419.
   Google Scholar
• •This paper reports the first 7-membered lactone compounds, which combine enhanced plasma stability and potent topo I-mediated activity.
   Google Scholar
• LESUEUR-GINOT L, DEMARQUAY D, KISS R et al.: Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res. (1999) 59:2939–2943.
   PubMed Web of Science ®Google Scholar
• URASAKI Y, TAKEBAYASHI Y, POMMIER Y: Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. Cancer Res. (2000) 60:6577–6580.
   Google Scholar
• CAO Z, PANTAZIS E MENDOZA J et al:Structure-activity relationships of alkyl camptothecin esters. In: The Camptothecins. Unfolding their Anti-Cancer potential. Liehr JG, Giovanella BC, Verschraegen CF (Eds), New York Academy of Sciences, USA (2000) 922:122–135.
   Google Scholar
• KEHRER DFS, SOEPENBERG O, LOOS WJ, VERWEIJ J, SPARREBOOM A: Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs (2001) 12:89–105.
   Google Scholar
• •A very comprehensive review on recent progress in camptothecin development.
   Google Scholar
• CAIOLFA VR, ZAMAI M, FIORINO A et al.: Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J. Contra/Re/ (2000) 65:105–119.
   Google Scholar
• CONOVER CD, GREENWALD RB, PENDRI A, SHUM KL: Camptothecin delivery systems: the utility of aminoacid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anticancer Drug Des. (1999) 14:499.
   PubMedGoogle Scholar
• SINGER JW, DE VRIES P, BHATT R et al.: Conjugation of camptothecins to poly-(L-glutamic acid). In: The Camptothecins. Unfolding their Ann-Cancer potential. Liehr JG, Giovanella BC, Verschraegen CF (Eds), New York Academy of Sciences (2000) 922:136–150.
   Google Scholar
• MASUBUCHI N, GOHDA R, SEKI H, HAYASHI K, ATSUMI R, INOUE K: The A-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f [III]: pharmacokinetic evaluation in normal and tumor-bearing mice. Proc. Am. Ass. Cancer Res. (2001) 42:376.
   Google Scholar
• OKUNO S, HARADA M, YANO T et al: Complete regression of xenografted human carcinomas by camptothecin analogue carboxymethyl dextran conjugate (T-0128). Cancer Res. (2000) 60:2988–2995.
   PubMed Web of Science ®Google Scholar
• LERCHEN HG, BAUMGARTEN J, VON DEM BRUCH K et al: Design and optimization of 20-0-linked camptothecin glycoconjugates as anticancer agents. I Med. Chem. (2001) 44:4186–4195.
   PubMed Web of Science ®Google Scholar
• TANIZAWA A, FUJIMORI A, FUJIMORI Y, POMMIER Y: Comparison of Topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. ..1 Natl. Cancer Inst. (1994) 86:836–842.
   PubMed Web of Science ®Google Scholar
• BURKE, TG, MISRA AK, WANI MC, WALL ME: Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry (1993) 32:5352–5364.
   PubMed Web of Science ®Google Scholar
• •This seminal paper indicated, for the first time, the importance of the drug lipophylicity and of the interaction with HSA for increasing the stability of the lactone form.
   Google Scholar
• HAUSEER F, KOCHAT H, SEETHARAMULU P etal.: BNP1350s (KarenitecinTm) superior molecular characteristics: enhanced therapeutic performance of novel lipophilic, lactone stable camptothecin analogues. 2001 AACR Annual Meeting, (USA) (2001): Abstr.559.
   Google Scholar
• CHOURPA I; RIOU JF; MILLOT JM et al.:Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA. Biochemistry (1998) 37:7284–7291.
   Google Scholar
• HERTZBERG RT, CARANFA MF, HOLDEN KG et al: Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. ..1 Med. Chem. (1989) 32:715–720.
   PubMed Web of Science ®Google Scholar
• LAVERGNE O, BIGG DCH: The other camptothecins: recent advances with camptothecin analogs other than irinotecan and topotecan. Bull. Cancer (1998) Spec. No. 1:51–58.
   Google Scholar
• BAILLY C, LANSIAUX A, DASSONNEVILLE L et al: Homocamptothecin, an E-ring modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Biochemistry (1999) 38:15556–15563.
   PubMed Web of Science ®Google Scholar
• DEMARQUAY D; HUCHET M; COULOMB H et al The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison. Anticancer Drugs (2001) 12:9–19.
   PubMed Web of Science ®Google Scholar
• DEMARQUAY D, COULOMB H, HUCHET M et al: The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor. Ann. NY Acad. Sci. (2000) 922:301–305.
   Google Scholar
• BOM D, CURRAN, DP, CHAVAN AY et al: Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. j Med. Chem. (1999) 42:3018–3022
   Google Scholar
• PEREGO P, DE CESARE M, DE ISABELLA P et al.: Novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res. (2001) 61:6034–6037.
   Google Scholar
• •The first publication describing non-cross-resistance of 7-modified camptothecins in BCRP-overexpressing cells.
   Google Scholar
• LARSEN AK, GILBERT C, CHYZAK G et al: Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res. (2001) 61:2961–2967.
   PubMed Web of Science ®Google Scholar
• EMERSON DL, BENDELE R, BROWN E et al.: Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin. Cancer Res. (2000) 6:2903–2912.
   PubMed Web of Science ®Google Scholar